)

Basilea Pharmaceutica (BSLN) investor relations material
Basilea Pharmaceutica H1 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Executive summary
Achieved 36.3% year-over-year revenue growth to CHF104M in H1 2025, with a 24.8% increase in Cresemba global in-market sales and 21.7% higher royalty income.
Launched Zevtera in the US, expanding commercial reach and addressing high unmet medical needs in severe infections.
Advanced pipeline with a second Phase III study for fosmanogepix and in-licensed ceftibuten-ledobarbactam, a Phase III-ready oral antibiotic for complicated UTIs.
Secured $39M in non-dilutive BARDA funding to support antifungal R&D.
Strengthened financial position through debt reduction, including CHF14.3M in convertible bond repurchases, and positive operating cash flow.
Financial highlights
Total revenue reached CHF104M in H1 2025, up 36% year-on-year, with Cresemba & Zevtera revenue at CHF90.5M (+23.5%).
Operating profit surged to CHF24M, a 160% increase year-on-year.
Net profit was CHF15.8M, down from CHF20.7M in 2024 due to a one-time tax benefit last year.
Net cash position improved to CHF50.7M as of June 30, 2025, from net debt of CHF-26.2M a year earlier.
Operating cash flow was CHF23.1M, up from CHF17.9M in 2024.
Outlook and guidance
FY 2025 revenue guidance updated to above CHF220M–225M, with Cresemba and Zevtera revenue projected at CHF190M and royalty income expected to grow 14% to CHF110M.
Operating profit for 2025 expected at approximately CHF50M, reflecting increased R&D investment.
R&D expenses projected to rise to CHF105M, mainly due to in-licensing costs.
Anticipate a 17% reduction in product revenue due to decreased supply to Pfizer, offset by royalty growth.
Focus on advancing antifungal pipeline, new asset scouting, and maintaining leadership in anti-infectives.
Next Basilea Pharmaceutica earnings date

Next Basilea Pharmaceutica earnings date

The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage